文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

院前氨甲环酸对创伤性颅内出血患者死亡率和神经功能结局的影响:一项来自院前氨甲环酸治疗创伤性脑损伤试验的亚组分析

The effects of prehospital TXA on mortality and neurologic outcomes in patients with traumatic intracranial hemorrhage: A subgroup analysis from the prehospital TXA for TBI trial.
PubMed 文献 · J Trauma Acute Care Surg · 2024-04-30
一句话结论对中重度创伤性脑损伤合并颅内出血患者,院前2克氨甲环酸单次推注较安慰剂和1克推注/1克输注方案可降低28天死亡率和6个月残疾评定量表评分。

该研究为院前氨甲环酸治疗创伤性脑损伤试验的二次分析,纳入初始CT显示颅内出血的541例患者。患者被随机分为院前2克氨甲环酸推注+院内生理盐水输注组、院前1克氨甲环酸推注+院内1克氨甲环酸输注组或安慰剂组。结果发现,2克推注组28天死亡率为17%,低于1克推注/1克输注组的26%和安慰剂组的27%,调整后差异分别为-10.2和-8.5个百分点;6个月残疾评定量表评分也低于其他两组,但6个月扩展格拉斯哥结局量表评分无组间差异。

要点

  • 在541例中重度创伤性脑损伤合并颅内出血患者中,院前2克氨甲环酸推注组28天死亡率为17%,1克推注/1克输注组为26%,安慰剂组为27%。
  • 2克推注组与安慰剂组28天死亡率调整后差异为-8.5个百分点(95%CI -15.9至-1.0),与1克推注/1克输注组差异为-10.2个百分点(95%CI -17.6至-2.9)。
  • 6个月残疾评定量表评分:2克推注组较1克推注/1克输注组低2.1分(95%CI -4.2至-0.02),较安慰剂组低2.2分(95%CI -4.3至-0.2)。
  • 6个月扩展格拉斯哥结局量表(GOSE)评分在各组间无差异。

适用人群与场景

  • 中重度创伤性脑损伤(格拉斯哥昏迷评分<13)且收缩压≥90毫米汞柱的成人患者,在受伤后2小时内纳入。
  • 本分析仅纳入初始CT显示颅内出血的亚组患者。

诊断标准与关键阈值

  • 中重度创伤性脑损伤定义为格拉斯哥昏迷评分<13。
  • 颅内出血通过初始CT诊断。

处置流程与药物剂量

  • 院前2克氨甲环酸推注,随后院内生理盐水输注。
  • 院前1克氨甲环酸推注,随后院内1克氨甲环酸输注。
  • 院前生理盐水推注,随后院内生理盐水输注(安慰剂)。

研究设计与关键结果

  • 研究类型:院前氨甲环酸治疗创伤性脑损伤试验(NCT01990768)的二次分析,该试验随机对照了966例患者。
  • 本分析纳入541例初始CT显示颅内出血的患者。
  • 28天死亡率:2克推注组17%,1克推注/1克输注组26%,安慰剂组27%。
  • 2克推注组与安慰剂组28天死亡率调整后差异为-8.5个百分点(95%CI -15.9至-1.0)。
  • 2克推注组与1克推注/1克输注组28天死亡率调整后差异为-10.2个百分点(95%CI -17.6至-2.9)。
  • 6个月残疾评定量表评分:2克推注组较1克推注/1克输注组低2.1分(95%CI -4.2至-0.02),较安慰剂组低2.2分(95%CI -4.3至-0.2)。
  • 6个月扩展格拉斯哥结局量表评分在各组间无差异。

证据类型、等级与局限

  • 证据类型:随机对照试验的亚组分析。
  • 证据等级:治疗/护理管理;Level II。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于中重度创伤性脑损伤合并颅内出血的患者,院前2克氨甲环酸单次推注可能降低28天死亡率和6个月残疾评定量表评分,作者认为该结果优于安慰剂和标准氨甲环酸给药方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In the prehospital tranexamic acid (TXA) for traumatic brain injury (TBI) trial, TXA administered within 2 hours of injury in the out-of-hospital setting did not reduce mortality in all patients with moderate/severe traumatic brain injury (TBI). We examined the association between TXA dosing arms, neurologic outcome, and mortality in patients with intracranial hemorrhage (ICH) on computed tomography (CT).

METHODS: This was a secondary analysis of the Prehospital Tranexamic Acid for TBI Trial ( ClinicalTrials.gov [NCT01990768]) that randomized adults with moderate/severe TBI (Glasgow Coma Scale score < 13) and systolic blood pressure ≥ 90 mm Hg within 2 hours of injury to a 2-g out-of-hospital TXA bolus followed by an in-hospital saline infusion, a 1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion, or an out-of-hospital saline bolus/in-hospital saline infusion (placebo). This analysis included the subgroup with ICH on initial CT. Primary outcomes included 28-day mortality, 6-month Glasgow Outcome Scale-Extended (GOSE) ≤ 4, and 6-month Disability Rating Scale (DRS). Outcomes were modeled using linear regression with robust standard errors.

RESULTS: The primary trial included 966 patients. Among 541 participants with ICH, 28-day mortality was lower in the 2-g TXA bolus group (17%) compared with the other two groups (1-g bolus/1-g infusion 26%, placebo 27%). The estimated adjusted difference between the 2-g bolus and placebo groups was -8·5 percentage points (95% confidence interval [CI], -15.9 to -1.0) and between the 2-g bolus and 1-g bolus/1-g infusion groups was -10.2 percentage points (95% CI, -17.6 to -2.9). Disability Rating Scale at 6 months was lower in the 2-g TXA bolus group than the 1-g bolus/1-g infusion (estimated difference - 2.1 [95% CI, -4.2 to -0.02]) and placebo groups (-2.2 [95% CI, -4.3, -0.2]). Six-month GOSE did not differ among groups.

CONCLUSION: A 2-g out-of-hospital TXA bolus in patients with moderate/severe TBI and ICH resulted in lower 28-day mortality and lower 6-month DRS than placebo and standard TXA dosing.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level II.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Rowell S, Meier EN, Hoyos Gomez T, et al. The effects of prehospital TXA on mortality and neurologic outcomes in patients with traumatic intracranial hemorrhage: A subgroup analysis from the prehospital TXA for TBI trial. J Trauma Acute Care Surg. 2024. PMID: 38685481. doi:10.1097/TA.0000000000004354

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。